|1.||Shlipak, Michael G: 72 articles (11/2015 - 01/2005)|
|2.||Katz, Ronit: 36 articles (02/2015 - 01/2005)|
|3.||Sarnak, Mark J: 29 articles (01/2015 - 01/2005)|
|4.||Fried, Linda F: 27 articles (03/2013 - 01/2005)|
|5.||Coresh, Josef: 25 articles (07/2015 - 07/2007)|
|6.||Peralta, Carmen A: 21 articles (10/2015 - 09/2006)|
|7.||Grubb, Anders: 21 articles (02/2015 - 09/2003)|
|8.||Larsson, Anders: 20 articles (02/2015 - 10/2004)|
|9.||Siscovick, David S: 19 articles (01/2015 - 05/2005)|
|10.||Ix, Joachim H: 19 articles (01/2015 - 08/2006)|
|1.||Kidney Diseases (Kidney Disease)
03/01/2015 - "J Am Soc Nephrol 2009;20:629-37; Schwartz et al. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. "
08/01/2012 - "Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C."
10/01/2014 - "The final study population included 37 patients with SCI. The Chronic Kidney Disease Epidemiology Collaboration cystatin C equation provided significantly less bias, greater precision, and superior accuracy when used in the PK model. "
03/01/2014 - "Chronic kidney disease defined by cystatin C predicts mobility disability and changes in gait speed: the Framingham Offspring Study."
01/01/2014 - "In this study, we aimed to determine whether standardized serum cystatin C (SCC) equation may be an applicability of marker for dialysis initiation and its relationship to other clearance values among patients with advanced chronic kidney disease. "
04/01/2007 - "Although a gold standard of kidney function is lacking, this analysis suggests that cystatin C captures an association of mildly impaired kidney function with increased inflammation."
07/01/2014 - "Studies have shown that both cystatin C and metabolic syndrome (MetS) are associated with inflammation. "
12/01/2010 - "This study showed that cystatin C is a marker of inflammation as well as renal function."
09/01/2010 - "Clinical studies involving direct glomerular filtration rate measurements are required to ascertain both the true role of this promising marker in renal disease and whether atherogenic factors like inflammation can account for increases in cystatin C concentrations, thus explaining its predictive value in CVD."
12/01/2009 - "Recent studies suggest that cystatin C can modulate matrix degradation and inflammation. "
01/01/2001 - "Patients with albuminuria above 200 microg/min exhibited a significant increase of cystatin c plasma concentrations and a significant reduction in mean glomerular filtration slit size. "
01/01/2014 - "In this study, we aimed to investigate the associations of both serum cystatin C levels and albuminuria with arterial stiffness in healthy controls and hypertensive patients. "
06/01/2011 - "We examined the association of cystatin C level and albuminuria with the development of CKD stage 3. Prospective observational study. "
02/01/2011 - "This study was done to evaluate clinical usefulness of cystatin C levels of serum and urine in predicting renal impairment in normoalbuminuric patients with type 2 diabetes and to evaluate the association between albuminuria and serum/urine cystatin C. "
11/01/2015 - "On the back of this, national and international guidelines including those of the National Institute for Health and Clinical Excellence have recommended the use of cystatin C to risk stratify individuals with mild to moderately reduced glomerular filtration rate and no albuminuria. "
|4.||Chronic Kidney Failure (Chronic Renal Failure)
07/01/2015 - "A >30% decline in kidney function assessed using novel filtration markers is associated strongly with ESRD, suggesting the potential utility of measuring change in cystatin C and B2M levels in settings in which improved outcome ascertainment is needed, such as clinical trials."
12/01/2005 - "Preliminary studies into early renal function decline, a process measured in early nephropathy using a simple assay for cystatin C to calculate the slope of glomerular filtration rate change over time, suggest that it is a more proximal marker than microalbuminuria of a person's trajectory toward impaired renal function and ESRD. "
05/01/2001 - "To study cystatin C kinetics in a rat model of end-stage renal failure. "
11/01/2012 - "Serum concentration of cystatin C and risk of end-stage renal disease in diabetes."
06/01/2012 - "Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis."
|5.||Liver Diseases (Liver Disease)
07/01/2005 - "A linear regression analysis has revealed a direct relationship between cystatin C and MMP-2 (Y=83.39 + 270.56 X, R=0.38, P< 0.001), as well as between MMP-2 and the severity of liver diseases. "
07/01/2005 - "A total of 154 consecutive patients with various liver diseases were recruited to determine their serum levels of cystatin C, MMP-2 and-9, together with other hepatic parameters. "
03/01/2004 - "Average serum cystatin C concentration of patients with hepatic diseases was significantly higher than that of control (0.0902+/-0.0025 mg/dl vs. 0.067+/-0.007 mg/dl; p<0.001), and a linear regression analysis has revealed a direct relation between cystatin C and the severity of liver diseases (Y=1.172+5.492X, R(2)=0.088, p<0.001). "
08/01/2001 - "Serum cystatin C concentrations were determined by an enzyme-linked immunosorbent assay kit in 103 patients with various chronic liver diseases and compared with concentrations in healthy control volunteers. "
08/01/2001 - "We examined serum cystatin C concentrations in patients to explore the possible clinical application of cystatin C as a marker of disease severity in cases of chronic liver diseases. "
|3.||Biological Markers (Surrogate Marker)
|4.||Brain Natriuretic Peptide (Natrecor)
|7.||Iothalamic Acid (Iotalamic Acid)
|1.||Transplantation (Transplant Recipients)
|2.||Drug Therapy (Chemotherapy)
|3.||Artificial Respiration (Mechanical Ventilation)
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)